We view IPCA as a structural growth story, with all business segments contributing to growth. We expect IPCA to report 30% EPS CAGR over FY14-16, led by international generics. We reiterate Buy, with a target price of INR 1,025 (16x FY16E EPS). IPCA is one of our preferred picks in the midcap healthcare space
READ MORE »Posts tagged IPCA Labs
IPCA Research Report By Microsec
We rate Ipca Laboratories Ltd. a ‘BUY’. Our rating underpins the company’s
strong management, its strategy of focusing on global generic and API business and R&D activities. Company is also focusing on formulation business & therapeutic coverage especially in the fast growing lifestyle related segment